Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Market Closed 01-23 16:00:00 EST

0.5030

-0.0070

-1.37%

盘后0.5050

+0.0020+0.40%

19:57 EST

High0.5299	Low0.5020	Vol2.13M
Open0.5273	D1 Closing0.5100	Amplitude5.47%
Mkt Cap32.25M	Tradable Cap24.54M	Total Shares64.11M
T/O1.09M	T/O Rate4.37%	Tradable Shares48.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.503,"timestamp":1769202000000,"preClose":0.51,"halted":0,"volume":2133855,"hourTrading":{"tag":"盘后","latestPrice":0.505,"preClose":0.503,"latestTime":"19:57 EST","volume":51435,"amount":25925.9557,"timestamp":1769216277989,"change":0.002,"changeRate":0.003976,"amplitude":0.015905},"delay":0,"changeRate":-0.013725490196078443,"floatShares":48780400,"shares":64114399,"eps":-1.794017,"marketStatus":"Market Closed","change":-0.007,"latestTime":"01-23 16:00:00 EST","open":0.5273,"high":0.5299,"low":0.502,"amount":1089821.203524,"amplitude":0.054706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.794017,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.51,"preHourTrading":{"tag":"盘前","latestPrice":0.5295,"preClose":0.51,"latestTime":"09:25 EST","volume":21298,"amount":11085.878206719999,"timestamp":1769178314093,"change":0.0195,"changeRate":0.038235,"amplitude":0.020392},"postHourTrading":{"tag":"盘后","latestPrice":0.505,"preClose":0.503,"latestTime":"19:57 EST","volume":51435,"amount":25925.9557,"timestamp":1769216277989,"change":0.002,"changeRate":0.003976,"amplitude":0.015905},"volumeRatio":0.948844385607872,"impliedVol":0.1607,"impliedVolPercentile":0.0438},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2601909978","title":"Press Release: Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601909978","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601909978?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:35","pubTimestamp":1767706500,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., Jan. 06, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.\"We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,\" said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. \"Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.\". In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be responsible for leading Outlook Therape","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APED","BK4139","BK4595","MSTW","07399","3LMI.UK","LU1064131342.USD","LU1951198990.SGD","MSTK","LU1242518931.SGD","LU0979878070.USD","MST","MSTY.UK","09799","LU1803068979.SGD","WNTR","09399","LU0889565833.HKD","BK4585","LU1880398471.USD","IMST","LU1951200564.SGD","MSII","LU2250418816.HKD","MSTP","OTLK","MSTZ","07799","SMI3.UK","03160","LU1316542783.SGD","MSST","IE0009356076.USD","MTYY","LENZ","LMI3.UK","MSTX","MSOO","BK4543","3SMI.UK","MSDD","SMST","BK4099","BK4023","TM","LU1242518857.USD","MSTY"],"gpt_icon":1},{"id":"2600067611","title":"Sector Update: Health Care Stocks Mixed in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067611","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600067611?lang=en_us&edition=fundamental","pubTime":"2026-01-03 02:50","pubTimestamp":1767379803,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index fractionally higher and the State Street Health Care Select Sector SPDR ETF  easing 0.1%.The iShares Biotechnology ETF  was down 0.6%.In corporate news, Ironwood Pharmaceuticals  shares jumped 29% after the company said it expects sales of its irritable bowel syndrome with constipation or chronic constipation treatment, Linzess, in the US to be higher this year compared with 2025.Outlook Therapeutics  shares fell 58% after the company said Wednesday the US Food and Drug Administration has issued a complete response letter for its ONS-5010 biologics license application resubmission.Hoth Therapeutics  shares climbed 4.4% after it said Friday it has filed two US provisional patent applications aimed at expanding its intellectual property portfolio and establishing an oncology-focused dermatology platform.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IRWD","BK4007","XBI","HOTH","BK4585","IBB","LABU","BK4581","OTLK","XLV","BK4588"],"gpt_icon":0},{"id":"2600064912","title":"Crude Oil Falls 1%; US Manufacturing Growth Eases In December","url":"https://stock-news.laohu8.com/highlight/detail?id=2600064912","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600064912?lang=en_us&edition=fundamental","pubTime":"2026-01-03 01:13","pubTimestamp":1767374029,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49671500/crude-oil-falls-1-us-manufacturing-growth-eases-in-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4603","BK4141","MNQmain","NVIW.SI","TSYW.SI","BK4134","BK4082","USAW.SI",".IXIC","SQQQ","QID","OTLK","BK4152","BK4139","IRWD","QLD","PSQ","NQmain","SELX","TQQQ","CHOW","USJW.SI","UAVS"],"gpt_icon":1},{"id":"2600618880","title":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM Resorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2600618880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600618880?lang=en_us&edition=fundamental","pubTime":"2026-01-02 23:42","pubTimestamp":1767368536,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM ResortsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nL6N3Y30DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","LU1366333091.USD","ESHA","LU0011850046.USD","LASE","LU0426412945.USD","BK4161","RBOT","HL","CDE","INTU","89888","OTLK","TSLA","WSM","IE00BK4W5L77.USD","CMG","RH","LU0053666078.USD","RIO.UK","MGM","RIO.AU","WDAY","LU0029864427.USD","IE00B894F039.SGD","LU1883866441.USD","RIVN","NEM","BHP.AU","HK0000320223.HKD","TSYW.SI","LU0127658192.USD","BK4596","AP","RAMP","KVYO","LU0061474960.USD","SCCO","W","IRWD","IE00BQXX3C00.GBP","LU0055631609.USD"],"gpt_icon":1},{"id":"2600065801","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2600065801","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600065801?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:08","pubTimestamp":1767359318,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) shares were down 61% in recent Friday premarket activity, after the company said Wednesday the US Food and Drug Administration has issued a complete response letter to the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","BK4082","BK4096","NVVE","BK4139","FMFC","BK4202"],"gpt_icon":1},{"id":"2600306331","title":"BUZZ-U.S. STOCKS ON THE MOVE-Silver and gold miners, Baidu, Outlook Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2600306331","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600306331?lang=en_us&edition=fundamental","pubTime":"2026-01-02 20:21","pubTimestamp":1767356491,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Silver and gold miners, Baidu, Outlook TherapeuticsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nL6N3Y309M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0287142896.SGD","LU0345780521.USD","BK4552","LU0300736492.USD","LU0612318971.USD","HL","LU0345780950.USD","LU1223082519.USD","GOLD","LU1115378108.SGD","LU0300736062.USD","SBSW","BK4210","LU1223082196.USD","BK4585","BK4614","LU0788108826.HKD","OTLK","LU0788109121.HKD","LU0055631609.USD","NEM","LU0359202008.SGD","BK4612","LU0496367417.USD","BK4533","CDE","LU1280957306.USD","LU0359201612.USD","LU1223083913.SGD","BK4526","BK4531","LU1883866441.USD","LU0498741890.SGD","LU0654597011.USD","BK4514","LU0724618789.USD","BK4587","BK4532","BK4570","BK4602","LU0640798160.USD","SVM","BK4139","BK4548","BK4579","LU0278409577.USD","LU0498741114.HKD","LU0266512473.USD","LU0456854461.SGD","LU0173614495.USD","LU0640476718.USD","LU1023059493.AUD","LU1023057109.AUD","LU0075056555.USD","GFI","BIDU","LU0345780281.USD","BK4535","BK4543","BK4588","LU0266512127.USD","LU0612318385.USD","HMY","IE00B0JY6N72.USD","EXK","LU1430597077.USD","LU0345781412.USD","LU0330918003.SGD","BK4504","BK4574","LU2462611646.USD","LU0630314457.HKD","LU0368265764.SGD","SG9999001143.SGD","BK4017","09888","BK4077","LU2498475776.HKD"],"gpt_icon":1},{"id":"2600050758","title":"BUZZ-Outlook Therapeutics plunges after FDA rejects eye drug for third time","url":"https://stock-news.laohu8.com/highlight/detail?id=2600050758","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600050758?lang=en_us&edition=fundamental","pubTime":"2026-01-02 19:13","pubTimestamp":1767352394,"startTime":"0","endTime":"0","summary":"BUZZ-Outlook Therapeutics plunges after FDA rejects eye drug for third time** Shares of Outlook Therapeutics OTLK.O plunge 59.6% to 64 cents premarket ** U.S. FDA declines to approve co's Lytenava for wet age-related macular degeneration, citing lack of confirmatory evidence of efficacy** Decision marks third rejection after earlier refusals in 2023 and Aug 2025** Lytenava, an eye disease-specific adaptation of bevacizumab, failed to match Roche's ROG.S Lucentis in key trial** Drug already approved in EU and UK; FDA has not indicated what type of confirmatory evidence would be acceptable** OTLK down 16.4% in 2025   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nL6N3Y308O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600057493","title":"Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2600057493","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600057493?lang=en_us&edition=fundamental","pubTime":"2026-01-02 18:12","pubTimestamp":1767348773,"startTime":"0","endTime":"0","summary":"U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher.\n\n\n\nThe Santa Claus trading period, which began on Dec. 24 last week, did not materialize as the S&amp;P 500 declined for the fourth straight session, despite recording gains for 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3e67a077c288ab67c7e5d0620ff37fd4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/01/49662968/stock-market-today-sp-500-dow-futures-gain-on-the-first-trading-day-of-2026-baidu-rubico-intelligent-bio-solutions-in-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVV","BK4082","LU0348825331.USD","LU0359201612.USD","BK4587","BK1095","HK0000320264.USD","HK0000320223.HKD","IE0034224299.USD","BK1609","LU0348735423.USD","LU0821914370.USD","SG9999014674.SGD","LU0630378429.USD","OEF","LU0315179316.USD","BK1587","BK1588","BK4559","LU0043850808.USD","BK4531","BK4612","LU0228367735.SGD","BK4535","BK4514","LU1328615791.USD","LU0856984785.SGD","SG9999002828.SGD","LU0640798160.USD","LU1048588211.SGD","INBS","OTLK","BK4548","LU0039217434.USD","BK4579","BK4602","BK4077","BK1575","LU0072462343.USD","LU0588546209.SGD","LU0456827905.SGD","LU0320764599.SGD","LU1481107354.HKD","LU0823426308.USD","LU0197773673.USD","LU0229945570.USD","BK1615","OEX","BK4543","LU0307460666.USD","LU0052750758.USD","LU0762540952.USD","SG9999002463.SGD","LU0708995583.HKD","LU0051755006.USD","BK4504","CHOW","LU0417516738.SGD","BK4574","LU2778985437.USD","09888","BK4134","HK0000306701.USD","SDS","BK4593","BK4581","BIDU","LU0287142896.SGD","BK4561","LU0831093199.SGD","LU2039709279.SGD","SSO","LU1048596156.SGD","LU0164880469.USD","LU0762542818.HKD","ESmain","BK4585","BK4614","LU0871576103.HKD","LU0823426480.USD","LU0197773160.USD","BK4588","BK4139","BK4550","LU0164865239.USD","LU0630378692.HKD","BK4552","HK0000306685.HKD","SH","LU1115378108.SGD","LU0762541174.USD","LU0819121731.USD","LU1023057109.AUD","LU0149721374.USD","RUBI","LU0173614495.USD","BK4144","LU0163747925.USD","BK4526","LU0326950275.SGD","IE00B0JY6N72.USD","LU2476274308.USD","89888","BK4534","SPXU","UPRO","LU0359202008.SGD","LU0417516902.SGD","LU0543330566.HKD","MESmain","LU0531971595.HKD"],"gpt_icon":1},{"id":"2600805258","title":"Outlook Therapeutics Shares Plunge 61.5% Premarket After US FDA Declines to Approve Eye Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600805258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600805258?lang=en_us&edition=fundamental","pubTime":"2026-01-02 17:04","pubTimestamp":1767344691,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y108B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600870287","title":"Stocks to Watch: Nuvve, Outlook Therapeutics, Rubico","url":"https://stock-news.laohu8.com/highlight/detail?id=2600870287","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600870287?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:51","pubTimestamp":1767221460,"startTime":"0","endTime":"0","summary":"Nuvve closed a private placement with gross proceeds of $5.4 million. Shares fell 14% to $2.18 in after-hours trading Wednesday.Outlook Therapeutics said the Food and Drug Administration rejected its application for a treatment of macular degeneration. The stock slid 69% to 49 cents after the bell.Rubico agreed to buy a vessel-owning company. Shares climbed 29% to $1.38.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4096","BK4139","NVVE","OTLK","BK4144","BK4539","BK4007","RUBI"],"gpt_icon":0},{"id":"2600704733","title":"BRIEF-Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava","url":"https://stock-news.laohu8.com/highlight/detail?id=2600704733","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600704733?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:36","pubTimestamp":1767220587,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava Dec 31 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS PROVIDES REGULATORY UPDATE ON U.S. FOOD AND","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600704580","title":"Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600704580","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600704580?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:05","pubTimestamp":1767218700,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration.The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year.The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration.Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for.In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","OTLK","BK4539"],"gpt_icon":0},{"id":"2600701922","title":"Outlook Therapeutics Says FDA Issued Complete Response Letter to ONS-5010 BLA Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701922","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701922?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:33","pubTimestamp":1767216792,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said Wednesday the US Food and Drug Administration has issued a complete response letter to the ONS-5010 biologics license application resubmission.The move indicates the regulator cannot approve the application in its present form for the treatment of wet age-related macular degeneration, the company said.Outlook Therapeutics said it is exploring \"all available pathways\" for potential clearance in the US and it also plans to continue its efforts to expand into more markets in Europe and other regions.Trading in shares of Outlook Therapeutics were halted.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4539","OTLK","BK4007"],"gpt_icon":0},{"id":"2600701342","title":"US FDA declines to approve Outlook Therapeutics' eye disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701342","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701342?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:19","pubTimestamp":1767215956,"startTime":"0","endTime":"0","summary":"US FDA declines to approve Outlook Therapeutics' eye disease drugDec 31  - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nL4N3Y10VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600701334","title":"Outlook Therapeutics Inc - FDA Issues Complete Response Letter for Ons-5010 Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701334?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600370135","title":"Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2600370135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600370135?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600332701","title":"Outlook Therapeutics Inc:  Currently Exploring All Available Pathways for Potential Approval in U.s","url":"https://stock-news.laohu8.com/highlight/detail?id=2600332701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600332701?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600013597","title":"Outlook Therapeutics Inc: FDA Has Not Indicated What Type of Confirmatory Evidence Would Be Acceptable","url":"https://stock-news.laohu8.com/highlight/detail?id=2600013597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600013597?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600701899","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:10 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701899","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701899?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:10","pubTimestamp":1767215400,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:10 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nAQN2LFYHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2594564215","title":"Outlook Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2594564215","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594564215?lang=en_us&edition=fundamental","pubTime":"2025-12-27 06:00","pubTimestamp":1766786409,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. has granted stock options to purchase a total of 150,000 shares of its common stock at an exercise price of $2.01 per share to two new employees, effective December 19, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251226:nNDL25sSdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","OTLK","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","SG9999014013.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","BK4585","BK4139","LU2095319765.USD","SG9999014039.USD","NDAQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0791},{"period":"1month","weight":-0.7251},{"period":"3month","weight":-0.6381},{"period":"6month","weight":-0.7534},{"period":"1year","weight":-0.7534},{"period":"ytd","weight":-0.6816}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.037275},{"month":2,"riseRate":0.444444,"avgChangeRate":0.160578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}